Drug intelligence / Profile preview

IMSET

Development stage: Preclinical
Lead developer: Evotec
Modality: RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Oral, Intravenous, Intramuscular

Overview

IMSET is a novel therapeutic under development by researchers at the University of Bristol's Bristol Medical School, with financial backing from beLAB1407, a component of Evotec's BRIDGE partnerships. This therapeutic is designed to address atherosclerosis by targeting a specific novel non-coding RNA, also identified as IMSET. Its mechanism involves modulating immune cell behavior, which is a key factor in the development of atherosclerotic plaques. The primary goal of IMSET is to offer a treatment option for patients who have previously suffered a heart attack or stroke.

Other names: IMSET

Targets

CDKN2B-AS1 (CDKN2B antisense RNA 1)

Beyond the preview

Go deeper on IMSET.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMSET.

Explore the full profile